Skip to main content
Equibles

PRELUDE CAPITAL MANAGEMENT, LLC

Position in MGNX — Macrogenics Inc

CIK 1387508 NEW YORK, NY
Back to MGNX Full portfolio

Position in MGNX

as of Jun 30, 2026 · filed Aug 14, 2026
Position Value
$121,506
+$60,587 QoQ
Shares Held
26,300
+83.5% QoQ
Ownership
0.041%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#80
of 122 holders
Holding Since
Jun 2020
7 quarters on record
Voting authority Sole 0% Shared 100% None 0%

Common Shares in MGNX Over Time

Shares Held

Position Value (USD)

Derivatives in MGNX

reported options exposure · as of Jun 30, 2020
CallValue
$0
CallShares
0
PutValue
$5,584
PutShares
200

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

PRELUDE CAPITAL MANAGEMENT, LLC holds $43,640,056 across 72 Biotechnology names. MGNX ranks #49 (0.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 APGE
Apogee Therapeutics, Inc.
 58,590 $7,776,650
2 TECH
BIO-TECHNE Corp
 91,696 $6,478,322
3 PGEN
Precigen, Inc.
 882,267 $5,028,921
4 ROIV
Roivant Sciences Ltd.
 113,104 $4,002,750
5 RVMD
Revolution Medicines, Inc.
 10,997 $2,059,518
6 TWST
Twist Bioscience Corp
 18,976 $1,952,250
7 QURE
uniQure N.V.
 32,229 $1,484,467
8 MDXG
Mimedx Group, Inc.
 215,239 $828,670

All Filings in MGNX

Export CSV
8 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $121,506 26,300
2024-06-30 $60,919 14,334
2023-12-31 $290,524 30,200
2023-09-30 $48,464 10,400
2023-06-30 $71,550 13,374
2020-09-30 $5,038 200
2020-06-30 $5,584 200
2020-06-30 $2,792 100